【24h】

Adjunctive corticosteroid therapy in pediatric severe sepsis: observations from the RESOLVE study.

机译:小儿严重脓毒症的辅助性糖皮质激素治疗:来自RESOLVE研究的观察结果。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

OBJECTIVE: To assess whether corticosteroids, used as adjunctive therapy for pediatric severe sepsis, is associated with improved outcomes. DESIGN: Retrospective cohort study examining the clinical database derived from the RESOLVE (REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective, F1K-MC-EVBP) trial of activated protein C for pediatric severe sepsis. SETTING: A total of 104 pediatric centers in 18 countries from which data were originally gathered. SUBJECTS: Children with severe sepsis (n = 477), requiring both vasoactive-inotropic infusions and mechanical ventilation. Within this cohort, 193 children received corticosteroids during their septic episode and 284 did not. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Baseline summary characteristics demonstrated that children receiving or not receiving corticosteroids had similar demographics and disease severity as indicated by age, gender, mean Pediatric Risk of Mortality scores, and mean number of organ dysfunctions. Use of adjunctive corticosteroids increased during the F1K-MC-EVBP trial. Indications for corticosteroid prescription were therapeutic (89%, mostly shock) and prophylactic (13%). All cause 28-day mortality among children receiving and not receiving corticosteroids was 15.1% and 18.8%, respectively, p = .30. There was no difference in mean vasoactive-inotropic infusion days between the corticosteroid and no corticosteroid groups, 4.5 days vs. 4.3 days, respectively, p = .59. Similarly there was no difference in mean ventilator days between the corticosteroid and no corticosteroid groups, 8.3 days vs. 7.7 days, respectively, p = .38. CONCLUSIONS: Children with severe sepsis who received adjunctive corticosteroid therapy exhibited similar illness severity compared with those who did not. No definitive improvement in outcomes can be attributable to adjunctive corticosteroid therapy in the largest pediatric sepsis trial conducted to date.
机译:目的:评估皮质类固醇作为小儿严重败血症的辅助治疗是否与改善预后相关。设计:一项回顾性队列研究,研究了从RESOLVE(研究儿童严重脓毒症和器官功能障碍:全球视角,F1K-MC-EVBP)活化蛋白C用于儿童严重脓毒症的临床数据库。地点:最初收集数据的18个国家/地区的104个儿科中心。对象:患有严重败血症的儿童(n = 477),需要同时进行血管活性正性输液和机械通气。在该队列中,有193名儿童在脓毒症发作期间接受了皮质类固醇激素治疗,而284名儿童则没有。干预措施:无。测量和主要结果:基线摘要特征表明,接受或未接受皮质类固醇激素治疗的儿童具有相似的人口统计学和疾病严重性,如年龄,性别,平均儿童死亡率风险得分和平均器官功能障碍数所表明。在F1K-MC-EVBP试验期间,辅助糖皮质激素的使用有所增加。皮质类固醇处方的适应症是治疗性的(89%,主要是休克)和预防性的(13%)。在接受和未接受皮质类固醇的儿童中,所有原因导致的28天死亡率分别为15.1%和18.8%,p = .30。皮质类固醇组和非皮质类固醇组的平均促血管收缩性输液天数分别为4.5天和4.3天,p = .59。同样,皮质类固醇组和无皮质类固醇组之间的平均呼吸机天数也没有差异,分别为8.3天和7.7天,p = 0.38。结论:与未接受皮质类固醇辅助治疗的重症败血症儿童相比,其病情严重程度相似。迄今为止最大的儿科脓毒症试验并未将辅助性糖皮质激素治疗归因于最终疗效的确切改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号